3-Year Outcome in Patients With Combined Precapillary and Postcapillary Pulmonary Hypertension: Results From PADN-5 Trial.

[1]  M. Humbert,et al.  2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension , 2022, European Respiratory Journal.

[2]  M. Link,et al.  2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Journal of the American College of Cardiology.

[3]  N. Jones,et al.  Survival of patients with chronic heart failure in the community: a systematic review and meta‐analysis , 2019, European journal of heart failure.

[4]  M. Hellmich,et al.  Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension. , 2019, International journal of cardiology.

[5]  Yaling Han,et al.  Pulmonary Artery Denervation Significantly Increases 6-Min Walk Distance for Patients With Combined Pre- and Post-Capillary Pulmonary Hypertension Associated With Left Heart Failure: The PADN-5 Study. , 2019, JACC. Cardiovascular interventions.

[6]  G. Simonneau,et al.  An overview of the 6th World Symposium on Pulmonary Hypertension , 2019, European Respiratory Journal.

[7]  Haniye Sadat Sajadi,et al.  Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, The Lancet.

[8]  G. Weisz,et al.  Pulmonary Hypertension with Left Heart Disease: Prevalence, Temporal Shifts in Etiologies and Outcome. , 2017, The American journal of medicine.

[9]  R. Naeije,et al.  Hemodynamic Phenotyping of Pulmonary Hypertension in Left Heart Failure , 2017, Circulation. Heart failure.

[10]  Gerasimos S Filippatos,et al.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of the American College of Cardiology.

[11]  Javed Butler,et al.  Six‐minute walk distance predicts 30‐day readmission after acute heart failure hospitalization , 2017, Heart & lung : the journal of critical care.

[12]  M. Guazzi,et al.  Pulmonary Hypertension in Heart Failure: Pathophysiology, Pathobiology, and Emerging Clinical Perspectives. , 2017, Journal of the American College of Cardiology.

[13]  G. Ferretti,et al.  Kinetics of Cardiac Output at the Onset of Exercise in Precapillary Pulmonary Hypertension , 2016, BioMed research international.

[14]  H. Verberne,et al.  Cardiac sympathetic activity in chronic heart failure: cardiac 123I-mIBG scintigraphy to improve patient selection for ICD implantation , 2016, Netherlands Heart Journal.

[15]  E. Horn,et al.  Group 2 Pulmonary Hypertension: Pulmonary Venous Hypertension: Epidemiology and Pathophysiology. , 2016, Cardiology clinics.

[16]  S. Rosenkranz,et al.  Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension: A Pathophysiological Continuum. , 2016, Journal of the American College of Cardiology.

[17]  G. Stone,et al.  Hemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension of Different Causes , 2015, Circulation. Cardiovascular interventions.

[18]  R. Wachter,et al.  Left ventricular heart failure and pulmonary hypertension , 2015, European heart journal.

[19]  Xiaojing Wu,et al.  Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta‐analysis , 2014, European journal of heart failure.

[20]  Sanjiv J. Shah,et al.  Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: Baseline Findings From the Echocardiographic Study of the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial , 2014, Circulation. Heart failure.

[21]  Toru Satoh,et al.  Definitions and diagnosis of pulmonary hypertension. , 2013, Journal of the American College of Cardiology.

[22]  B. Borlaug,et al.  Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure. , 2013, JACC. Heart failure.

[23]  Simon Stewart,et al.  Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort , 2012, Heart.

[24]  R. Nishimura,et al.  Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. , 2012, Journal of the American College of Cardiology.

[25]  Sanjiv J. Shah,et al.  Clinical Characteristics of Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction , 2011, Circulation. Heart failure.

[26]  E. Catherwood,et al.  Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. , 2010, The American journal of cardiology.

[27]  R. Arena,et al.  Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Target of Phosphodiesterase-5 Inhibition in a 1-Year Study , 2009, Circulation.

[28]  V. Roger,et al.  Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. , 2009, Journal of the American College of Cardiology.

[29]  R. Gerszten,et al.  Sildenafil Improves Exercise Capacity and Quality of Life in Patients With Systolic Heart Failure and Secondary Pulmonary Hypertension , 2007 .

[30]  L. Tavazzi,et al.  Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. , 2001, Journal of the American College of Cardiology.